PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för BI-2536. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

28 hits

Bibliografisk träff 2024-04-30

Comprehensive quantifications of tumour microenvironment to predict the responsiveness to immunotherapy and prognosis for paediatric neuroblastomas.

Song M, Sun Y, Hu Y, Wang C, Jin Y, Liu Y, Da Y, Zhao Q, Zheng R, Li L.

Int Immunopharmacol · journal article · DOI 10.1016/j.intimp.2024.112145

Bibliografisk träff 2024-03-27

A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro.

Wu X, Wu J.

Cancer Chemother Pharmacol · research-article; journal article · DOI 10.1007/s00280-024-04654-8

Bibliografisk träff 2023-12-08

Eph signal inhibition potentiates the growth-inhibitory effects of PLK1 inhibition toward cancer cells.

Yuki R, Kuwajima H, Ota R, Ikeda Y, Saito Y, Nakayama Y.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2023.176229

Bibliografisk träff 2023-10-18

Cellular Heterogeneity of Activated Primary Human Macrophages and Associated Drug-Gene Networks: From Biology to Precision Therapeutics.

Decano JL, Maiorino E, Matamalas JT, Chelvanambi S, Tiemeijer BM, Yanagihara Y, Mukai S, Jha PK, Pestana DVS, D'Souza E, Whelan M, Ge R, Asano T, Sharma A, Libby P, Singh SA, Aikawa E, Aikawa M.

Circulation · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1161/circulationaha.123.064794

Bibliografisk träff 2023-07-21

Polo‑like kinase 1 selective inhibitor BI2536 (dihydropteridinone) disrupts centrosome homeostasis via ATM‑ERK cascade in adrenocortical carcinoma.

Lin RC, Chao YY, Lien WC, Chang HC, Tsai SW, Wang CY.

Oncol Rep · research-article; journal article · DOI 10.3892/or.2023.8604

Bibliografisk träff 2022-09-30

Polo-like kinase inhibitor BI2536 induces eryptosis.

Jemaà M, Mokdad Gargouri R, Lang F.

Wien Med Wochenschr · journal article · DOI 10.1007/s10354-022-00966-7

Bibliografisk träff 2022-08-23

The mitotic regulator polo-like kinase 1 as a potential therapeutic target for c-Myc-overexpressing canine osteosarcomas.

Gola C, Licenziato L, Accornero P, Iussich S, Morello E, Buracco P, Modesto P, Aresu L, De Maria R.

Vet Comp Oncol · research-article; journal article · DOI 10.1111/vco.12854

Bibliografisk träff 2022-08-09

BI 2536 induces gasdermin E-dependent pyroptosis in ovarian cancer.

Huo J, Shen Y, Zhang Y, Shen L.

Front Oncol · research-article; journal article · DOI 10.3389/fonc.2022.963928

Bibliografisk träff 2022-05-20

Shedding light on the binding mechanism of kinase inhibitors BI-2536, Volasetib and Ro-3280 with their pharmacological target PLK1.

Fernández-Sainz J, Pacheco-Liñán PJ, Granadino-Roldán JM, Bravo I, Rubio-Martínez J, Albaladejo J, Garzón-Ruiz A.

J Photochem Photobiol B · journal article · DOI 10.1016/j.jphotobiol.2022.112477

Bibliografisk träff 2021-12-28

BI-2536 Promotes Neuroblastoma Cell Death via Minichromosome Maintenance Complex Components 2 and 10.

Hsieh CH, Yeh HN, Huang CT, Wang WH, Hsu WM, Huang HC, Juan HF.

Pharmaceuticals (Basel) · research-article; journal article · DOI 10.3390/ph15010037

Bibliografisk träff 2020-10-22

Calibrated liposomal release of the anti-mitotic agent BI-2536 increases the targeting of mitotic tumor cells.

Ng CZ, Ann Matthews A, Sum R, Goh SMP, Xu A, Yap LW, Cheong I.

Eur J Pharm Biopharm · comparative study; journal article · DOI 10.1016/j.ejpb.2020.10.006

Bibliografisk träff 2020-10-16

Connectivity Mapping Identifies BI-2536 as a Potential Drug to Treat Diabetic Kidney Disease.

Zhang L, Wang Z, Liu R, Li Z, Lin J, Wojciechowicz ML, Huang J, Lee K, Ma'ayan A, He JC.

Diabetes · comment; research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.2337/db20-0580

Bibliografisk träff 2020-03-05

The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells.

Li Z, Yang C, Li X, Du X, Tao Y, Ren J, Fang F, Xie Y, Li M, Qian G, Xu L, Cao X, Wu Y, Lv H, Hu S, Lu J, Pan J.

J Cancer · research-article; journal article · DOI 10.7150/jca.33110

Bibliografisk träff 2019-09-13

Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold.

Remillard D, Buckley DL, Seo HS, Ferguson FM, Dhe-Paganon S, Bradner JE, Gray NS.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.9b00243

Bibliografisk träff 2018-02-23

BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.

Gohda J, Suzuki K, Liu K, Xie X, Takeuchi H, Inoue JI, Kawaguchi Y, Ishida T.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-018-21942-5

Bibliografisk träff 2017-05-12

Binding of the anticancer drug BI-2536 to human serum albumin. A spectroscopic and theoretical study.

Fernández-Sainz J, Pacheco-Liñán PJ, Granadino-Roldán JM, Bravo I, Garzón A, Rubio-Martínez J, Albaladejo J.

J Photochem Photobiol B · journal article · DOI 10.1016/j.jphotobiol.2017.05.016

Bibliografisk träff 2016-12-30

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).

Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, Bonomi PD, Ellison DM, Eaton KD, Fritsch H, Munzert G, Johnson BE, Socinski MA.

Lung Cancer · clinical trial, phase ii; multicenter study; journal article · DOI 10.1016/j.lungcan.2016.12.019

Bibliografisk träff 2015-05-18

BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536.

Chen L, Yap JL, Yoshioka M, Lanning ME, Fountain RN, Raje M, Scheenstra JA, Strovel JW, Fletcher S.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.5b00084

Bibliografisk träff 2015-01-01

Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.

Valianou M, Cox AM, Pichette B, Hartley S, Paladhi UR, Astrinidis A.

Cell Cycle · research support, non-u.s. gov't; report; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.4161/15384101.2014.986394

Bibliografisk träff 2014-02-12

PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia.

Oliveira JC, Pezuk JA, Brassesco MS, Morales AG, Queiroz RG, Scrideli CA, Tone LG.

Pediatr Blood Cancer · clinical trial; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1002/pbc.24978

Bibliografisk träff 2013-08-17

Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.

Wu CP, Hsiao SH, Sim HM, Luo SY, Tuo WC, Cheng HW, Li YQ, Huang YH, Ambudkar SV.

Biochem Pharmacol · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.bcp.2013.08.004

Bibliografisk träff 2012-05-01

In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells.

de Oliveira JC, Brassesco MS, Pezuk JA, Morales AG, Valera ET, Montaldi AP, Sakamoto-Hojo ET, Scrideli CA, Tone LG.

J Drugs Dermatol · research support, non-u.s. gov't; journal article

Bibliografisk träff 2012-05-01

Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.

Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, Kriener S, Engels K, Pleli T, Benz A, Canamero M, Longerich T, Kronenberger B, Richter S, Waidmann O, Vogl TJ, Zeuzem S, Piiper A.

Neoplasia · research support, non-u.s. gov't; research-article; journal article · DOI 10.1596/neo.111366

Bibliografisk träff 2011-11-12

Antiproliferative in vitro effects of BI 2536-mediated PLK1 inhibition on cervical adenocarcinoma cells.

Pezuk JA, Brassesco MS, Oliveira JC, Morales AG, Montaldi AP, Sakamoto-Hojo ET, Scrideli CA, Tone LG.

Clin Exp Med · journal article · DOI 10.1007/s10238-011-0166-1

Bibliografisk träff 2011-04-01

Polo-like kinase 1 inhibitors SBE13 and BI 2536 induce different responses in primary cells.

Eckerdt F.

Cell Cycle · comment; news

Bibliografisk träff 2011-04-01

Polo-like kinase 1 inhibitors SBE13 and BI 2536 induce different responses in primary cells.

Eckerdt F.

Cell Cycle · journal article · DOI 10.4161/cc.10.7.15213

Bibliografisk träff 2010-09-24

The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro.

Lu B, Mahmud H, Maass AH, Yu B, van Gilst WH, de Boer RA, Silljé HH.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0012963

Bibliografisk träff 2007-02-08

The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

Lénárt P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM.

Curr Biol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.cub.2006.12.046